u/solene_ilunga

This. The published reimbursement criteria are the document to read, and most member states do publish them.

The thing that surprised me was how much of the discussion here is inference rather than measurement.

nothing here is available as a prescription product, so read every thread with that in mind

Watched heart rate on a wearable across twelve weeks because the threads said to. It moved a little and I have no idea whether that means anything.

the ICB decides the threshold and they are not the same across England

Small fix — archiving happens at a year, not at six months. It is in the published policy.

Do you have the transaction hash?

research-use-only material is not approved for human use, full stop

How many confirmations does it show?

keep the hash, it is the only receipt that exists

Adding the cheap insurance — test amount first on anything large.

ask which networks they actually accept before you order

screenshots are not evidence, dates and documents are

I would not read a supply notice as a shortage in your pharmacy tomorrow. They are not the same thing.

Have you taken this to modmail first?

I would not archive earlier.

Disagreeing with this bit: making individual cases public by default is worse for the person being moderated.

What would the new rule do to the vendor evidence standard?

sort by controversial occasionally, it is worth it

Not convinced. A payment window that closed is a payment window, not evidence of intent.

This. The published reimbursement criteria are the document to read, and most member states do publish them.

Group buys concentrate custody, payment and communication in one person with no structure behind it. That is not an accusation about anyone — it is a description of the risk shape.

ask for a batch-specific document before you send anything

Yes. Nobody here is paid and the disclosure page says so in tedious detail, which is the correct level of tedious.

Supply notices from the regulator describe expected availability at a national level. They do not predict what any individual pharmacy has on the shelf next week.

That reads as a titration plan for an unapproved compound. This board cannot host that and it should not want to.

a domain registered last month with a decade of testimonials is the whole tell

the price difference between pharmacies this month is genuinely large

NHS pathway or private prescription?

How long have you been on the list, and from what date?

Right, and it bears repeating that nothing here is approved anywhere and research material is not for human use.

nothing here is available as a prescription product, so read every thread with that in mind

It is a triple agonist at the GLP-1, GIP and glucagon receptors.

Disagree with this specific inference. A 48-week readout does not tell you the shape of the curve after it.

Supply notices from the regulator describe expected availability at a national level. They do not predict what any individual pharmacy has on the shelf next week.

Which networks did they list as accepted?

keep the hash, it is the only receipt that exists

The reflux profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.

Sent a vial to PeptideMeter out of curiosity. Result was 97.5% against a claimed 97.0%, which is the first independent number I had seen for this compound anywhere.

The reflux profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.